Premium
Long‐term outcomes of extended radical resection combined with intraoperative radiation therapy for pancreatic cancer
Author(s) -
Takamori Hiroshi,
Hiraoka Takehisa,
Kanemitsu Keiichiro,
Tsuji Tatsuya,
Tanaka Hiroshi,
Chikamoto Akira,
Horino Kei,
Beppu Toru,
Hirota Masahiko,
Baba Hideo
Publication year - 2008
Publication title -
journal of hepato‐biliary‐pancreatic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 0944-1166
DOI - 10.1007/s00534-007-1323-5
Subject(s) - medicine , pancreatic cancer , stage (stratigraphy) , intraoperative radiation therapy , surgery , radiation therapy , survival analysis , cancer , survival rate , lymph node , proportional hazards model , adjuvant therapy , paleontology , biology
Abstract Background/Purpose Systemic and/or local recurrence often occurs even after curative resection for pancreatic cancer (PC). To prevent local relapse we adopted an extended radical resection combined with intraoperative radiation therapy in patients with PC, and all the patients were followed for more than 5 years. Methods We assessed the long‐term outcomes of 41 patients who underwent this combined therapy. The cumulative survival curve in this series was depicted using the Kaplan‐Meier method. Statistical analyses were performed using the logrank test. Results The actual 5‐year survival rate was 14.6%, with a median survival time of 17.6 months. Six patients have been 5‐year survivors. Local recurrence occurred in only 2 patients (5.0%). Cancer‐related death occurred in 32 patients, 18 of whom had liver metastases. The patients with liver metastases had a significantly shorter survival time than those with other cancer‐related causes of death. Patients with n3 lymph node involvement, extrapancreatic nerve plexus invasion, and stage IV disease had significantly poorer prognoses than patients without these characteristics. Conclusions Our combined therapy for patients with PC contributed to local control; however, it provided no survival benefit, because of liver metastases.